The Centre Hospitalier Universitaire Vaudois (CHUV), the European Laboratory for Particle Physics (CERN) and THERYQ (ALCEN Group) have entered a deal for the development of an advanced FLASH radiotherapy device.

Based on CERN technology, the device will use very high-energy electron (VHEE) radiation for the treatment of cancers that are resistant to conventional treatments.

It would reduce side effects while increasing effectiveness on tumours by reducing irradiation to a few milliseconds.

The tripartite deal includes planning, development, regulatory compliance, and construction of the radiotherapy device using the FLASH technique.

THERYQ, a part of ALCEN’s healthcare division, will manufacture the device, which will include a compact linear accelerator based on CERN technology.

The company’s FLASHDEEP tool will use VHEE beams of 100MeV to 200MeV by integrating CERN’s innovative compact linear accelerator technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This will allow the new FLASH radiotherapy device to treat all types of cancers up to a depth of 20cm.

Claimed to be the world’s first radiotherapy device, the FLASH radiotherapy device is expected to be operational within two years, with the first clinical trials planned for 2025.

Upon completion, the device will be installed at CHUV.

CHUV director-general Philippe Eckert said: “As a university hospital, the CHUV is fully committed to research. FLASH therapy embodies the spirit of innovation that drives us in this field.

“Eager to offer the most effective techniques to patients, we have joined forces with a world-class research centre and a cutting-edge industrial partner to solve a medical, physical and technical problem and find innovative solutions to fight cancer.”